Randomized trial of the anti-FGF23 antibody KRN23 in X-linked hypophosphatemia

2014313 citationsJournal Article

Authors

Thomas O. Carpenter · Yale University

Erik A. Imel

Mary D. Ruppe · Methodist Hospital

Thomas J. Weber · Duke Medical Center

Mark A. Klausner · Kyowa Hakko Kirin (Singapore)

Margaret M. Wooddell · Kyowa Hakko Kirin (Singapore)

Tetsuyoshi Kawakami · Kyowa Hakko Kirin (Singapore)

Abstract

KRN23 increased TmP/GFR, serum Pi, and serum 1,25(OH)2D. The positive effect of KR23 on serum Pi and its favorable safety profile suggest utility for KRN23 in XLH patients. Trial registration. Clinicaltrials.gov NCT00830674. Funding. Kyowa Hakko Kirin Pharma, Inc.

Topics & Keywords

Parathyroid Disorders and Treatments Medical Imaging and Pathology Studies Magnesium in Health and Disease

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Investigation

Volume 124, Issue 4, pp. 1587-1597

DOI: 10.1172/jci72829

Field-Weighted Citation Impact: 17.43